-
-
-
-
-
-
-
SELLAS Life Sciences (SLS) Reports Positive Phase 2 Preliminary Data of SLS009
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX) Announces FDA Approval of INGREZZA SPRINKLE Capsules
-
-
-
-
-
-
-
INmune Bio (INMB) Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years
-
-
-
-
-
-
-
Immunic Inc. (IMUX) phase 2 EMPhASIS trial data published in Neurology Neuroimmunology & Neuroinflammation
-
-
-
-
-
-
-
Immix Biopharma (IMMX) Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
-
-
-
-
-
-
-
Soleno Therapeutics (SLNO) Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
-
-
-
-
-
-
-
Prime Medicine (PRME) announces fda clearance of investigational new drug (ind) application for pm359 for the treatment of chronic granulomatous disease
-
66,958 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.